-

Shareholder Alert: Robbins LLP Announces Exela Technologies Inc. (XELA) Accused of Misleading Shareholders

SAN DIEGO & IRVING, Texas--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of Exela Technologies Inc. (NASDAQ: XELA) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between March 16, 2018 and March 16, 2020. Exela provides transaction processing solutions, enterprise information management, document management, and digital business process services worldwide.

If you suffered a loss as a result of Exela's misconduct, click here.

Exela Technologies Inc. (XELA) Accused of Misleading Shareholders

According to the complaint, in Exela's 2017 and 2018 annual reports and in its first through third quarter 2019 reports, the Company attested to its accuracy of financial reporting, the disclosure of any material changes to the Company’s internal controls over financial reporting, and the disclosure of all fraud. Despite these assurances, on March 16, 2020, Exela issued a press release revealing that it would be delaying its earnings release and earnings call due to "the delayed filing of its Form 10-K for the year-ended December 31, 2019, and the need to restate certain of its historical financial statements." The following day, Exela further elaborated on the situation in its notice of late filing with the SEC, stating that the Company would need to restate its financial statements for 2017, 2018, and interim periods through September 30, 2019 "to correct certain historical accounting errors" as a result of a material weakness in its internal control over financial reporting. Following these disclosures, Exela's share price fell 23% to close at $0.145 per share on March 18, 2020.

Exela Technologies Inc. (XELA) Shareholders Have Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Want to be notified if a class action on behalf of Exela settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:XELA

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the FS KKR Capital Corp. Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired FS KKR Capital (NYSE: FSK) securities between May 8, 2024 and February 25, 2026. FS KKR Capital is a private credit firm, also known as Business Development Company, which specializes in making private loans to companies.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Ro...

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...

Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? January 19, 2026 – March 25, 202...
Back to Newsroom